



12 April 2021

Manager Companies
Company Announcements Office
Australian Stock Exchange Limited

Dear Sir

**Results of Extraordinary General Meeting
Probiotec Limited**

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise the results of the resolutions, and the proxies received in respect of each resolution are set out in the attached summary.

Yours Sincerely

Jared Stringer
Company Secretary



**Probiotec Limited - Extraordinary General Meeting
Summary**

**Proxy & Results
12 April 2021**

1. APPROVAL OF FINANCIAL ASSISTANCE

In Favour	Against	Abstain/Exclusion	Proxy's Discretion (unvoted)
39,302,750	13,485	49,573	16,567

The motion was carried via poll.

**2. RATIFICATION OF PRIOR ISSUE OF SHARES TO MULTIPACK-LJM VENDORS
IN CONNECTION WITH THE MULTIPACK-LJM ACQUISITION**

In Favour	Against	Abstain/Exclusion	Proxy's Discretion (unvoted)
39,387,800	13,485	5,356	16,567

The motion was carried via poll.

**3. RATIFICATION OF AGREEMENT TO ISSUE DEFERRED CONSIDERATION
SHARES TO MULTIPACK-LJM VENDORS IN CONNECTION WITH THE
MULTIPACK-LJM ACQUISITION**

In Favour	Against	Abstain/Exclusion	Proxy's Discretion (unvoted)
39,382,800	13,485	10,356	16,567

The motion was carried via poll.

About Probiotec

Probiotec Limited is a manufacturer, packer and distributor of a range of prescription and over-the-counter (OTC) pharmaceuticals, complementary medicines, FMCG and consumer health products. The company owns five manufacturing facilities in Australia and distributes its products both domestically and internationally. Products are manufactured by Probiotec on behalf of a range of clients, including major international companies.

Further details about Probiotec are available at www.probiotec.com.au

Authorised for release by the board of directors.

For further information contact:

Mr Wes Stringer, Managing Director
(03) 9278 7555